BiPar Innovation Board

Hoyoung Huh, M.D., Ph.D., Chairman of the Board

Dr. Huh led the merger with the French pharmaceutical firm sanofi-aventis (EURONEXT: SAN and NYSE: SNY) for $500 million in April 2009. BiPar is now an independent, wholly owned subsidiary and center of innovation within the sanofi-aventis corporation.

Dr. Huh has been involved in the formation, management and board positions of multiple biotechnology and innovation-based companies.  He currently serves as the Chairman of the Board of Epizyme, Inc., a novel biopharmaceutical company in the area of epigenetics based in Cambridge, Massachusetts.  He also serves on the Board of Directors at Facet Biotech (NASDAQ: FACT), BayBio, SciDose LLC, Interplast, and on the Presidential Advisory Council of the Berklee College of Music.  He was previously a member of the Board of Directors, Chief Operating Officer, and Head of the PEGylation Business Unit at Nektar Therapeutics (NASDAQ: NKTR), a drug development company focused on oncology, CNS/pain, diabetes and infectious diseases.  At Nektar, Dr. Huh engineered and led significant, partnerships with major pharmaceutical companies, including Bayer, Roche, Baxter, Novartis, and Pfizer.

As an industry thought leader, Dr. Huh speaks frequently on innovation, entrepreneurship, and biotechnology strategies.  Dr. Huh was formerly a Partner at McKinsey and Company, where he was a leader in the biotechnology and biopharmaceutical sectors.  Dr. Huh holds an M.D. from Cornell University Medical College, a Ph.D. in Genetics/Cell Biology from the Cornell University/Sloan-Kettering Institute, and a bachelor's degree in biochemistry from Dartmouth College.

Barry Sherman, M.D.

Dr. Sherman, former Executive Vice President of Development and a founding member of BiPar Sciences, has more than 30 years of experience in academic and pharmaceutical biomedical research. He served as President and CEO of Anergen Inc., a founder of Pain Therapeutics, Inc., and as Genentech's first Senior Vice President and Chief Medical Officer. He has also been a board member and consultant to several biotechnology and pharmaceutical companies.

Prior to joining Genentech in 1985, Dr.Sherman was Professor of Medicine and Endocrinology at the University of Iowa-College of Medicine, where he served as Associate Chairman of the Department of Internal Medicine and Director of the National Institutes of Health-sponsored Clinical Research Center.

Dr. Sherman is a graduate of the University of Michigan in Ann Arbor, where he received both his A.B. and M.D.degrees with honors. He completed his clinical and research training at the Albert Einstein College of Medicine in New York, the NIH in Bethesda, Maryland, and the University of Michigan. He has contributed more than 125 publications to the scientific literature, including articles, chapters and books resulting from his NIH-funded laboratory and human investigation and results from the study of new pharmaceuticals.